How Many Exosomes or Stem Cells Are in a Vial? How Particle and Cell Counts Are Measured and Documented

By Stem Nova Network | April 2026 | 8 min read | For licensed medical professionals only

It is one of the most common questions licensed practitioners ask when evaluating biologic suppliers: does the number on the label actually matter, and how was it measured? What does "77 billion EVs" or "25 million cells" on a label actually represent — and what documentation should stand behind it?

These are the right questions to ask. And the honest answer is more nuanced than most suppliers will tell you. This post explains how exosome particle counts and MSC cell counts are measured, what can make two labeled numbers non-comparable, and what documentation licensed practitioners should request before evaluating any product in this category.

The Honest Starting Point: A Label Count Is a Measurement, Not a Dose

Before diving into the research, practitioners should understand the fundamental reality: there is no FDA-approved, consensus-established dosing standard for exosome biologics or UCT-MSC stem cells in outpatient regenerative medicine. What exists is a growing body of preclinical research, early-stage clinical trials in specific medical contexts, and extrapolated practice from clinicians working in this space. This article does not address dosing; it addresses how label numbers are measured and documented.

This is not a reason to dismiss particle counts or cell numbers — it is a reason to understand them more carefully. When a supplier lists 10 billion or 77 billion EVs on a label, the useful question is not "is that enough?" but "measured how, at what production stage, and documented where?"

The number is only as meaningful as its documentation — verified by NTA on the final shipped product and reported on a lot-specific Certificate of Analysis.

How Exosome Particle Counts Are Measured

Nanoparticle Tracking Analysis (NTA) on the final product

Nanoparticle Tracking Analysis (NTA) tracks the motion of individual particles in suspension to estimate particle concentration and size distribution. Stem Nova Network uses NanoSight NTA. For a label count to be meaningful, it should be measured on the final shipped product — not estimated from culture yield or taken at an upstream production stage — with the lot number, measured concentration, and size distribution reported on the COA.

Measurement stage matters as much as the number itself. A count taken before freezing, lyophilization, or fill is not the same as a count on the vial that ships. Two labels that state the same number may reflect different measurement stages, which is why the COA should state where in the process the count was taken.

Culture method and manufacturing yield

Not all exosome particle counts are equivalent even at the same number. Based on articles retrieved from PubMed, research published in Stem Cell Research & Therapy directly compared EVs produced in 3D bioreactor culture versus conventional 2D flat-surface culture — and found that 3D bioreactor conditions produced approximately 100 times higher EV yield per cell under that study's manufacturing conditions (DOI: 10.1186/s13287-024-03681-9).

That is a manufacturing-yield finding, not a product-effect claim. Culture method affects how many EVs a manufacturing run produces, which is why it belongs in supplier documentation alongside — not in place of — NTA verification of the final product.

How UCT-MSC Cell Counts and Viability Are Documented

Total cell count at fill

For UCT-MSC products, the labeled number (for example, 25 million or 10 million cells) is the total cell count at fill, determined by a validated cell-counting method at the time of cryopreservation. The COA should identify the counting method, the lot number, and the fill date.

The total count alone does not tell you what fraction of those cells are viable. That is a separate measurement, and it should be reported separately on the lot documentation.

Viability: a separate, lot-specific measurement

Viability is typically assessed with a dye-exclusion or flow-cytometry-based method and expressed as the percentage of cells that are viable. Stem Nova Network hUCT-MSC lots are documented at 97% viability. Ask whether any supplier's viability figure is lot-specific or a category average, and which method produced it.

Viability applies to cell products only. It is not a metric for exosomes, which are cell-free vesicles; for exosomes, the relevant documentation is NTA particle concentration and size distribution.

The Documentation Questions That Matter More Than "How Many"

The more useful framework for practitioners is not "how many" but rather a multi-variable assessment of how the labeled number was produced and documented:

What This Means for Product Evaluation

When practitioners are comparing products labeled "10 billion EVs," "77 billion EVs," and "150 billion EVs," the number is a starting point — not a conclusion. Here is what to confirm in the documentation:

Stem Nova Network's Product Formats in Context

Stem Nova Network's product formats are documented as follows:

All exosome products are 3D bioreactor-cultured from Wharton's Jelly UCT-MSC origin, stored frozen at −80 °C, and NTA-verified on the final shipped product. Every order ships with a lot-specific dual-lab Certificate of Analysis. Products are manufactured in an FDA-Registered Facility, cGTP-compliant (21 CFR Part 1271), USA Manufactured.

Frequently Asked Questions